![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/03/21/2406643/28889/en/Fortress-Biotech-Cyprium-Therapeutics-and-Sentynl-Therapeutics-Announce-CUTX-101-Copper-Histidinate-Data-to-be-Presented-at-2022-American-College-of-Medical-Genetics-Annual-Clinica.html
https://www.globenewswire.com/news-release/2021/12/07/2347337/28889/en/Fortress-Biotech-Cyprium-Therapeutics-and-Sentynl-Therapeutics-Announce-the-Initiation-of-Rolling-Submission-of-a-New-Drug-Application-for-CUTX-101-Copper-Histidinate-for-Treatment.html
https://www.globenewswire.com/news-release/2021/10/08/2311134/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-Positive-Clinical-Data-for-CUTX-101-Copper-Histidinate-Presented-at-2021-American-Academy-of-Pediatrics-National-Conference-Exhib.html
https://www.contractpharma.com/contents/view_breaking-news/2021-02-24/cyprium-sentynl-therapeutics-ink-asset-purchase-agreement/?widget=listSection
https://www.globenewswire.com/news-release/2021/02/24/2181393/0/en/Cyprium-Therapeutics-a-Fortress-Biotech-Partner-Company-and-Sentynl-Therapeutics-a-Wholly-owned-Subsidiary-of-the-Zydus-Group-Sign-Development-and-Asset-Purchase-Agreement-for-Cypr.html